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Abstract 
An increasing body of evidence appears to implicate the lipid bilayer of multidrug resistant (MDR) cells with P-glycoprotein activity. 
Several cationic amphiphilic drugs (CADs) have been extensively described as modulators of MDR. These same agents are also known to 
(1) inhibit lysosomal acid sphingomyelinase (ASmase), a phospholipid egrading enzyme, and/or (2) induce phospholipidosis in animal 
tissues or cultured cell lines. In this report, we randomly selected 17 CADs and evaluated their potency in modulating MDR in the murine 
MDR P388/ADR leukemia cell line. We compared these results with their ability to inhibit ASmase and observed a significant 
dose-dependent linear relationship (95% central confidence interval), between ASmase inhibition and MDR reversal. This approach 
permitted us to identify three new modestly potent chemosensitizers: trimipramine, desipramine, and mianserine. Modulation of MDR 
was not cell line specific, since CADs at 10 /zM increased oxorubicin (DOX) and vinblastine (VBL) (but not methotrexate, MTX) 
cytotoxicity in both P388/ADR and the human MDR cell lines MES-SA/Dx5 and K562/R7, but not in the parental drug-sensitive c lls. 
Although all chemosensitizing CADs at 10 /zM significantly increased Rhodamine-123 (Rho-123) accumulation i the human leukemia 
MDR cell line K562/R7 and most presented significant displacement of the photoaffinity labelling probe iodoarylazidoprazosin, no 
correlation between these ob,;ervations and the ability of CADs to sensitize MDR cells to DOX and VBL was found. In conclusion, our 
study strongly suggests that the chemosensitizing potency of agents uch as CADs may be due to a dual mechanism of action: direct 
antagonism of P-gp activity and indirect modulation of P-gp activity through the disruption of cellular lipid metabolism. 
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I. Introduction 
Mammalian cells selected in vitro for resistance to the 
anthracycline antibiotic doxorubicin (DOX) are typically 
cross-resistant to a wide variety of hydrophobic ytotoxic 
agents (multidrug resistance, MDR) (for review see Ref. 
[1]). The altered pharmacology of drugs in MDR cells 
(decreased accumulation and retention) appears to be me- 
diated by the overexpression f the gene product of MDR1, 
Abbreviations: CADs, cationic amphiphilic drugs; DOX, doxorubicin; 
VBL, vinblastine; MTX, methot:rexate; DNR, daunorubicin; MDR, mul- 
tidrug resistance; P-gp, P-glycoprotein; M'IT, 3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyltetrazolium; ASmase, lysosomal acid sphingornyelinase; 
Rho-123, rhodamine-123 
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a high molecular mass integral membrane protein, P-glyco- 
protein (P-gp) [2]. The clinical significance of MDR is 
supported by studies suggesting that the overexpression f 
the gene encoding for P-gp occurs in patients [3,4]. 
The sequence of P-gp is similar to certain bacterial 
transport proteins [5-7] and is ATP-dependent [8-12]. It 
appears to act as a relatively nonspecific energy-dependent 
drug-efflux pump responsible for decreased rug levels in 
MDR cells. The extraordinarily broad substrate specificity 
of P-gp has led to speculation as to the identity of the 
factor(s) which determine how it recognizes its substrate. 
Recently, Higgins and Gottesman [13], and Zordan-Nudo 
et al. [14] proposed that P-gp substrates may initially 
interact with the lipid bilayer before gaining access to P-gp 
by partitioning into the lipid phase. Indeed, the implication 
of lipids in transport processes via transmembrane proteins 
2 J.-P. Jaffrdzou et al./Biochimica et Biophysica Acta 1266 (1995) 1-8 
is a well-established phenomenon (for review see Ref. 
[15]), supported recently by several reports which have 
dearly shown that P-gp-mediated ATP hydrolysis is de- 
pendent on the lipid environment [10-12]. A strong sug- 
gestion of a link between lipids and the family of MDR 
gene products is provided by the observation of Smit et al. 
that the mouse mdr2 gene, which is 90% homologous to a 
second human P-gp gene MDR3, codes for a protein 
which plays an essential role in phospholipid transport 
[16]. Finally, both Callaghan et al. and Wadkins and 
Houghton have recently proposed that the interaction of 
chemosensitizers with cellular lipids is a contributing fac- 
tor in MDR modulation [17,18]. 
Previously, we have described a potent MDR modula- 
tor, SR33557, which did not directly interact with P-gp 
[19]. We also suggested that the mechanism of action of 
this novel chemosensitizer may be linked to its inhibitory 
effect on lysosomal acid sphingomyelinase (ASmase). In 
order to further investigate he role of altered lipid compo- 
sition in modulating MDR, we randomly selected 17 
cationic amphiphilic drugs (CADs), 14 of which have 
previously been reported to modulate MDR [19-25]. All 
have previously been described elsewhere as either having 
an inhibitory effect on ASmase, or inducing generalized 
lipidosis (phospholipid storage disorders) in cultured cell 
lines and/or tissues (for review see Ref. [26]). We deter- 
mined the potency of these agents in inhibiting ASmase 
activity in the murine MDR P388/ADR leukemia cell 
line, and in modulating resistance to DOX and vinblastine 
(VBL). 
2. Materials and methods 
SR33557 ((2-isopropyl- 1 ((4-(3-N-methyl-N-(3,4-di- 
methoxy-fl-phenethyl)amino)propyloxy)benzenesulfonyl))- 
indolizine) and its derivatives, SR33510 (1-~-hydroxybe- 
nzinesulfinyl-2-isopropylindolizine), a d SR45813 (N-(3- 
chloro-l-propyl)-N-methyl-3,4-phenethylamine) were a 
generous gift from Dr. Pierre Chatelain (Sanofi-Labaz 
Research Center, Brussels, Belgium) [27]. Perhexiline ana- 
logues Pex 2, Pex 5, Pex 7, and Pex 15 were provided by 
Dr. Decker (Institut de Pharmacologie, UA 589 CNRS, 
Facult6 de M6decine, Strasbourg, France) [28]. DOX was 
obtained from Adria Laboratories (Columbus, OH), VBL 
from Eli Lilly (Indianapolis, IN), and methotrexate from 
Lederle Parenterals (Carolina, Puerto Rico). CADs and all 
other agents were purchased from Sigma Chemical Co. 
(St. Louis, MO). CADs were solubilized in dimethyl sul- 
foxide or, if insoluble, in sterile distilled water. Dimethyl 
sulfoxide concentrations in assays never exceeded 0.1% 
(v/v). 
2.1. Cell culture 
The murine leukemia P388 cell line and the MDR 
subline P388/ADR were originally obtained from Dr. J.G. 
Mayo (Mammalian Genetics and Animal Production 
Branch, National Cancer Institute, Bethesda, MD). The 
cells were maintained in RPMI 1640 medium (M6rieux, 
Lyon, France) supplemented with 10% heat-inactivated 
fetal calf serum (Flow Laboratories, McLean, VA), 2 mM 
glutamine, 20/zM fl-mercaptoethanol, and antibiotics (200 
units penicillin/ml, 100 /xg streptomycin/ml). The hu- 
man sarcoma MES-SA and its MDR variant MES-SA/Dx5 
[29], as well as the erythroleukemia cell line K562 and its 
MDR subline K562/R7 [30] are permanently maintained 
in our laboratory. These cells were grown in McCoy's 
medium (Irvine Scientific, Santa Ana, CA) supplemented 
as described above. Cells were maintained at 37°C in a 
humidified atmosphere containing 5% CO 2. Cell stocks 
were screened routinely for Mycoplasma by the DNA 
hybridization method (Gen-Probe, San Diego, CA). 
2.2. MTT  cytotoxicity assay 
P388 and P388/ADR cells (6.105 cells/500/xl) were 
incubated in complete medium with and without drugs for 
1 h at 37°C in an atmosphere of 5% CO 2. Cells were then 
washed and resuspended at 2.105 cells/ml, and 0.1-ml 
aliquots were removed and seeded in 96-well multiplates 
for a further 48 h drug-flee incubation. MES-SA, MES- 
SA/Dx5, K562, and K562/R7 cells were directly seeded 
in 96-well plates (8000 cells/well) and incubated with and 
without drugs for 72 h at 37°C. Growth inhibition was 
evaluated by the M'Iq" colorimetric method on triplicate 
assays as previously described [19,31]. The absorbance 
was quantitated with a ThermoMax microplate reader 
(Molecular Devices, Menlo Park, CA). The ICs0 (drug 
concentration resulting in 50% inhibition of MT'F dye 
formation, compared to controls) was determined directly 
from semilogarithmic dose-response curves. 
2.3. Determination of acid sphingomyelinase activity 
Enzymatic activity was determined as described previ- 
ously [32]. 5 • 10  6 cells treated with or without CADs for 1 
h at 37°C were washed with 0.9% NaC1 and the cell pellets 
were resuspended in distilled water and sonicated. Protein 
concentrations were determined by the procedure of Hartree 
[33]. Briefly, a fluorescent pyrenesulfonylamidounde- 
canoyl sphingomyelin substrate was added to sonicated 
suspension i the presence of Triton X-100 for 2 h at 37°C. 
The reaction was stopped by the addition of 1.5 ml heptane 
and 0.45 ml isopropyl alcohol, followed by 0.25 ml water, 
and centrifugation at 1000 × g for 10 min. The product of 
the enzyme reaction, ceramide (which is linked to the 
fluorescent moiety), was determined fluorometrically by 
analyzing the upper heptane-rich phase at 351 and 378 nm 
(excitation and emission wavelengths, respectively). This 
product was quantitated by measuring the fluorescence 
intensity of known quantities of fluorescent ceramide 
(standard curve). The sphingomyelinase activity in treated 
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cells is expressed as nmoles of ceramide/h/mg protein 
and is compared to that of untreated cells. 
Alternatively, ASmase activity was determined (with 
similar results) by using t]he natural [14C]choline-labelled 
substrate, under previously reported conditions [34]. 
2.4. Flow cytometric assays 
Accumulation of Rhodamine-123 (Rh-123) was carried 
out essentially as previously described [35]. K562 and 
K562/R7 cells were passed through a nylon filter, cen- 
trifuged, and suspended in modified Hank's balanced salt 
solution (HBSS) containing 10 mM Hepes and 5% calf 
serum. Aliquots of 1 ml containing 2.5-105 cells were 
incubated with or without CADs at 37°C for 1 h. Rh-123 
was added to give a final concentration of 0.1 /zg/ml, 
followed by 45 min incubation at 37°C. Cells were cen- 
trifuged and the pellet resuspended in 200 /zl of ice-cold 
HBSS. Accumulation of Rh-123 was determined with a 
fluorescence activated cell sorter (FACStar, Becton-Dick- 
inson Corp., Mountain View, CA). 
2.5. Photoaffinity labelling studies 
Displacement of the P-I~ probe iodoaryl azidoprazosin 
was performed essentially as previously described [36,37]. 
K562 and K562/R7 cells (100/zg protein) were incubated 
with [125I]iodoaryl azidoprazosin (81.4 TBq/mmol, NEN- 
Dupont, Boston, MA) with and without CADs in a 10 mM 
Tris-HC1 buffer (pH 7.4) at a final volume of 50/xl. These 
preparations were incubated at 25°C for 1 h in the dark, 
followed by a 20 min exposure to a 366 nm UV source 
(UVP, San Gabriel, CA). 50 /zl of loading buffer was 
added and proteins eparated on a 6% polyacrylamide-SDS 
gel. Immunodetection using the anti-P-gp monoclonal nti- 
body C219 [38] (Centocor, Malvern, PA) was performed 
using the light-enhanced chemiluminescence W stern Blot 
protocol (Amersham Corp., Arlington Heights, IL), fol- 
lowed by autoradiography and densitometry. 
Table 1 
Modulation of doxorubicin and vinblastine r sistance by CADs in mul- 
tidrug resistant P388/ADR cells 
CAD Fold reversal  
DOX (/~M) VBL (p.M) 
1 3 6 10 10 
Coronary vasodilators 
Perhexiline 1.0 6.0 8.0 12.0 3.0 
Pex 2 1.0 1.0 1.0 1.0 1.0 
Pex 5 1.0 1.0 1.0 1.0 1.0 
SR33557 1.0 3.0 9.0 20.0 2.0 
Amiodarone 1.2 1.9 3.6 5.2 2.8 
Antimalarials 
Chloroquine 1.0 1.0 2.0 3.0 1.8 
Quinacrine 1.7 8.2 8.5 10.0 2.7 
Tranquillizers 
Chlorpromazine 1.0 2.5 nd 5.5 2.0 
Trifluoperazine 1.3 1.3 1.4 5.0 3.0 
Thioridazine 1.0 5.4 9.2 9.2 2.5 
Prochlorperazine 1.0 1.0 2.0 4.0 3.0 
Antidepressants 
Imipramine 1.0 1.0 1.7 1.7 1.5 
Desipramine 1.0 3.2 4.5 4.5 1.6 
Clomipramine 1.0 2.0 3.2 3.9 2.3 
Mianserine 1.0 1.0 2.4 10.0 2.6 
Trimipramine 2.3 2.4 2.5 3.9 1.7 
Other 
Tamoxifen 1.5 3.7 6.0 7.4 3.5 
a Fold reversal is the product of DOX or VBL concentration that 
inhibited cell growth by 50% in 48 h (IC50) divided by the IC50 of DOX 
or VBL in the presence of CADs. Values are means of at least wo 
independent experiments with S.D. < 10%. 
nd, not determined. 
ferent CADs presented istinct dose-effect curves. The 
most potent DOX modulators were perhexiline, SR33557, 
and quinacrine. These CADs were also effective at modu- 
lating VBL resistance in P388/ADR cells (Table 1), but 
had no effect on the non-MDR related drug methotrexate 
(MTX) (data not shown). None of the CADs had any 
significant impact on the parental drug-sensitive cell line 
P388 (data not shown). 
2.6. Statistical analysis 3.2. Inhibition of lysosomal acid sphingomyelinase activity 
Statistical calculations were performed using StatView 
software (Abacus Concepts, Berkeley, CA). Significance 
and confidence limits were estimated as described by 
Dowdy and Wearden [39]. 
3. Resu l ts  
3.1. Modulation of DOX and VBL resistance 
The dose-dependent effect of 17 CADs on DOX and 
VBL resistance was tested for in P388/ADR cells. A wide 
diversity in DOX modulating potency was observed with 
no overridding dose-effect profile (Table 1). Indeed, dif- 
Parallel to the DOX and VBL resistance modulation 
assay, the same series of CADs were tested for their ability 
to inhibit ASmase activity in P388/ADR cells. The com- 
pounds were tested at concentrations ranging from 0.1 to 
100 /xM. All CADs that modulated DOX and VBL resis- 
tance presented significant dose-effects within the micro- 
molar range. Table 2 shows most of the results of these 
experiments. Except for chloroquine, inhibition of ASmase 
activity was dose-dependent wi hin the micromolar range. 
However, as in the resistance modulation assays these 
CADs did not present similar dose-effect profiles. For 
example, certain agents such as tamoxifen and trim- 
ipramine shouldered-off at about the 3 /xM concentration 
while CADs such as perhexiline presented a linear dose-re- 
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Table 2 
Acid sphingomyelinase activity inhibition by CADs in multidrug resistant 
P388/ADR cells 
CAD Inhibition of sphingomyelinase activity (%) a 
CAD concentration (gM)  
1 3 6 10 
Coronary vasodilators 
Perhexiline 35 51 60 82 
Pex 2 nd nd 0 22 
Pex 5 nd nd 0 0 
SR33557 11 13 26 31 
Amiodarone 0 26 33 34 
Antimalarials 
Chloroquine 19 13 8 11 
Quinacrine 0 43 44 61 
Tranquillizers 
Chlorpromazine 12 40 nd 47 
Trifluoperazine 28 35 52 55 
Thioridazine 0 18 nd 51 
Prochlorperazine 28 33 35 46 
Antidepressants 
Imipramine 15 26 36 33 
Desipramine 0 25 nd 42 
Clomipramine 0 4 25 23 
Mianserine 0 6 13 52 
Trimipramine 6 33 33 39 
Other 
Tamoxifen 15 69 77 79 
a The inhibition of sphingomyelinase activity was measured as described 
in Section 2. Percentages were determined by dividing the residual 
activity in treated cells with that of untreated cells and subtracting it from 
100%. Values are means of at least two independent experiments with 
S.D. < 10%. 
nd, not determined. 
sponse from 1 to 10 /xM. Quinacrine, on the other hand, 
had a biphasic effect. The most potent ASmase inhibitors 
were perhexiline, SR33557 (at 20-30 /zM, see Ref. [19]), 
quinacrine, and tamoxifen. Inhibition of ASmase by CADs 
was only observed on treated intact cells, and not on cell 
sonicates. 
3.3. Correlation between inhibition o f  ASmase activity and 
modulation of  MDR 
Since it clearly appeared that inhibitors of ASmase 
could also modulate MDR within the same concentration 
range, we directly compared both effects. Fig. 1 compares 
the ASmase inhibition activity of these CADs at 10 /~M 
against heir DOX chemosensitizing potency. These data 
demonstrated good correlation ( r= 0.80, r 2 = 0.64) be- 
tween these two activities. When residuals were plotted 
against he independent variable (ASmase inhibition), very 
little differences in variance were seen (Fig. 1, inset). This 
relationship was estimated to be linear at the 0.05 level of 
significance. Furthermore, the equation of the straight line 
model (y- -0 .13 × (+0.17) -  0.21) can be used for pre- 
diction with a 95% central confidence interval as estimated 
by the one-tailed t-test at a = 0.05. Fig. 2 compares the 
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Fig. 1. Comparison between percent inhibition of ASmase activity by 
CADs used at 10/zM and fold-reversal of DOX resistance in P388/ADR 
cells. P388/ADR cells were incubated with CADs listed in Table 1 as 
described in Section 2. The impact of these agents at 10 /~M on both 
reversal of DOX resistance and inhibition of ASmase activity as listed in 
Tables 1 and 2 were plotted against each other (excluding SR33557). A 
linear relationship was estimated with the following definitions: y = 0.13 
× (+0.17) -0 .21,  r = 0.80, r 2 = 0.64, t Statistic = 4.80 (P  < 0.001), 
and F-ratio = 23.06 (P  < 0.001). 
dose-dependent ASmase inhibition of CADs against heir 
DOX chemosensitizing potency. Again, the relationship 
was estimated to fit a straight line model with good 
correlation (r = 0.70, r 2 -0.49),  and the line's equation 
(y = 0.09 × (+0.11)+ 0.65) can be used for prediction 
with a 95% central confidence interval. In this case, the 
plotted residuals show slightly greater variance as the 
x-axis (ASmase inhibition) increases, but remain within an 
acceptable range (Fig. 2, inset). In these comparative 
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Fig. 2. Comparison between the dose-effects of CADs on both inhibition 
of ASmase activity and fold-reversal of DOX resistance in P388/ADR 
cells. P388/ADR cells were incubated with CADs listed in Table 1 as 
described in Section 2. The impact of these agents at 1, 3, 6, and 10/zM 
on both reversal of DOX resistance and inhibition of ASmase activity as 
listed in Tables 1 and 2 were plotted against each other. A linear 
relationship was estimated with the following definitions: y = 0.09× 
(+0.11)+0.65, r = 0.70, r 2 = 0.49, t Statistic = 7.39 (P  < 0.001), and 
F-ratio = 54.64 (P  < 0.001). 
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Fig. 3. Comparison between percent inhibition of ASmase activity by 
CADs used at 10 p.M and fold-n~versal of VBL resistance in P388/ADR 
cells. P388/ADR cells were incubated with CADs as described in 
Section 2. The impact of these drugs at 10 ~M on both reversal of VBL 
resistance and inhibition of ASmase activity as listed in Tables 1 and 2 
were plotted against each other. A linear relationship was estimated with 
the following definitions: y = 0.03 × (+0.08)+ 1.12, r = 0.78, r 2 = 0.61, 
t Statistic = 4.92 (P  < 0.001), and F-ratio = 24.22 (P  < 0.001). 
powerful chemosensitizer most likely entails other mecha- 
nisms of action at this cortcentration [40]. 
In an effort to determine if such correlations could also 
be found with another MDR-related drug, we compared 
the ASmase inhibition of CADs with their ability to modu- 
late VBL resistance in the P388/ADR cell line. Fig. 3 
shows that there indeed exists such a correlation. The 
straight line model having the equation y = 0.03 × 
(+0.08) + 1.12 (r = 0.78, r 2 = 0.61). Finally, structural 
analogues of SR33557 (SR33510 and SR45813), of per- 
hexiline (Pex 7 and Pex 15), and 0.1% dimethyl sulfoxide 
had no effect either on ASmase or MDR reversal (data not 
shown). 
3.4. Characterization of three new chemosensitizers 
In order to determine if the three CADs which have 
never been previously de,;cribed as chemosensitizers (de- 
sipramine, mianserine, and trimipramine) are truly modula- 
tors of MDR, we tested these agents on two other MDR 
cell lines, MES-SA/Dx5 and K562/R7. As shown in 
Table 3, all three CADs presented modest chemosensitiz- 
ing activity for DNR and VBL on the MDR cell lines, 
whereas they did not have any effect on the parental 
drug-sensitive cell line MES-SA and K562 (data not 
shown). Furthermore, these CADs had no effect on MTX 
cytotoxicity on these cell lines. 
3.5. Flow cytometry analysis of rhodamine-123 accumula- 
tion 
In order to confirm that CADs inhibited the activity of 
P-gp, we evaluated their impact on Rho-123 accumulation 
in the MDR cell line K562/R7. As shown in Table 4, all 
CADs at 10 /xM significantly increased Rho-123 accumu- 
lation in K562/R7 cell line, whereas they had no such 
effect on the parental drug-sensitive K562 cell line. Struc- 
tural analogues of SR33557 (SR33510 and SR45813), of 
perhexiline (Pex 7 and Pex 15), and 0.1% dimethyl sulfox- 
ide had no effect on Rho-123 accumulation (data not 
shown). 
3.6. Photoaffinity labelling studies 
In an attempt to further characterize the mechanism of 
action of CADs, we performed photoaffinity labelling 
studies on the K562/R7 cell line using the P-gp probe 
[125I]iodoaryl azidoprazosin. Although a number of CADs 
significantly displaced the radiolabelled P-gp probe (10% 
to 40%) at 10 gM (Table 5), no correlation was observed 
between their ability to displace azidoprazosin binding and 
their chemosensitizing potency. Furthermore, two of the 
most potent chemosensitizers SR33557 and quinacrine, 
along with desipramine and clomipramine, presented less 
than a 10% inhibition of photolabelling. 10 /xM vinblas- 
tine, used as a positive control, displaced 67% of azidopra- 
zosin binding. 
Table 3 
Modulation of multidrug resistance by CADs in MES-SA/Dx5 and K562/R7 cells 
Anticancer drug CAD (10/xM) Anticancer drug IC5o a (/xM) 




none 0.03 9.50 0.034 1.43 
desipramine 4.75 (2.0) b 0.65 
mianserine 3.96 (2.4) 0.65 
triraipramine 2.79 (3.4) 0.51 
none 0.006 2.20 0.004 0.18 
desipramine 1.22 (1.8) 0.09 
miansefine 1.29 (1.7) 0.12 
tdraipramine 0.40 (5.5) 0.08 
none 0.17 0.19 0.04 0.04 
desipramine 0.23 0.04 
mi.'mserine 0.21 0.06 







a Concentration of anticancer dntg that inhibited cell growth by 50% in 72 h. Values are means of at least three independent experiments (S.D. < 10%). 
b Values in parentheses represenl fold reversal which is the ICso for anticancer drug alone divided by theICso for drug in the presence of chemosensitizer. 
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4. Discussion 
MDR cells are characterized by impaired drug accumu- 
lation associated with an increased expression of P-gp that 
is believed to be an energy-dependent drug-effiux pump 
[1]. However, as recently pointed out, the paradox is 
substrate specificity [13]. Not only does P-gp recognize, 
with moderate to low affinity, a diverse group of anti- 
cancer drugs, but there is an equally impressive variety of 
structurally diverse agents which modulate MDR [41]. 
Presently, the precise mechanisms involved in P-gp speci- 
ficity remain speculative but the cationic amphiphilic na- 
ture of most of these drugs suggests that a strong interac- 
tion can and will occur with certain polar lipids resulting 
in complexes formed by hydrophobic and electrostatic 
forces [42]. These drugs are most often CADs and contain 
a hydrophobic domain and an ionizable nitrogen (which 
can become protonated) [26,43,44]. 
Higgins and Gottesman have suggested that P-gp may 
interact with drugs which are intercalated within the lipid 
bilayer; they also proposed that differences in membrane 
lipid composition could affect drug partitioning and there- 
fore explain the variable resistance patterns een for P-gp 
in different umor cell lines [13]. Indeed, the participation 
of the lipid phase in P-gp activity has recently been 
strengthened by the observation that substrate stimulation 
of P-gp-mediated ATP hydrolysis was found only when 
the protein was reconstituted within a phospholipid vesicle 
[10-12]. Further evidence for the role of the lipid bilayer 
Table 4 
Effect of CADs on Rho-123 accumulation in K562/R7 MDR cells and 
the parental drug-sensitive cell line K562 
CAD (10/zM) Rho-123 concentration (Fold increase) ~
K562 K562/R7 P 
Coronary vasodilators 
Perhexiline 0.57 _+ 0.12 b 3.93 _+ 1.02 0.0041 
SR33557 1.05 _+ 0.24 12.13 _+ 1.23 0.0085 
Amiodarone 0.55 _+ 0.15 5.93 _+ 1.63 0.0434 
Antimalarials 
Chloroquine 1.00 + 0.06 1.37 -I- 0.11 0.0041 
Quinacrine 1.30 _+ 0.17 10.87 _+ 2.97 0.0038 
Tranquillizers 
Chlorpromazine 0.80 + 0.10 1.80 + 0.25 0.0113 
Trifluoperazine 0.73 -+ 0.07 2.80 _+ 0.29 0.0099 
Thioridazine 0.67 _+ 0.07 4.83 + 1.27 0.0038 
Prochlorperazine 0.70 _+ 0.10 3.93 _+ 1.17 0.0062 
Antidepressants 
Imipramine 0.83_+0.12 1.93_+0.19 0.0120 
Desipramine 0.87 _+ 0.03 2.00 _+ 0.11 0.0030 
Clomipramine 0.70 + 0.06 2.27_+ 0.32 0.0132 
Mianserine 1.00 _+ 0.35 1.37 _+ 0.20 0.2204 
Trimipramine 0.77 _+ 0.12 1.97 5:0.47 0.0722 
Other 
Tamoxifen 1.00-+0.15 2.00-+0.11 0.0467 
Rho-123 accumulation was measured asdescribed in Section 2. 
b Values are means of at least hree independent experiments ___ S.E. 
c p values were calculated using the paired one-tailed Student's t-test. 
Table 5 
Inhibition of [125I]iodoaryl azidoprazosin photolabeling to P-glycoprotein 
by CADs 






















a K562/R7 cells were photolabeled with [125I]iodoaryl azidoprazosin in 
the absence and in the presence of 10 /~M CADs as described inSection 
2. Analysis by Western blot of identical samples using the monoclonal 
antibody C219 confirmed the identity of P-glycoprotein. 
in modulation of MDR has been provided by Callaghan et 
al., who demonstrated that amphiphiles which affect mem- 
brane fluidity increase drug accumulation in MDR cells 
[17]. Finally, Wadkins and Houghton have recently charac- 
terized the interaction between a series of structurally 
diverse CADs and several lipids. Their results indicated 
that the interaction of CADs with lipids should be consid- 
ered as playing a role in modulation of MDR [18]. 
The implication of the lipid phase in P-gp activity may 
shed some light on the mechanisms of action of chemosen- 
sitizers. Several CADs have previously been described as 
inhibiting ASmase activity on various cultured cell lines 
[43-47]. Such inhibitors of ASmase generally cause the 
accumulation of its substrate, sphingomyelin, within the 
cells leading to lipidosis and often aberrant constitutional 
and morphological alterations in membranes [19,43]. In 
other studies, these same CADs, used at similar concentra- 
tions, have also been described as modulating MDR; these 
include perhexiline, chlorpromazine, trifluoperazine, 
prochlorperazine, imipramine, clomipramine, quinacrine, 
and dibucaine [20-25]. Such observations raise the possi- 
bility of a link between inhibition of P-gp activity and 
either phospholipidosis and/or  ASmase inhibition. 
In an effort to test the above-mentioned hypothesis, we 
randomly selected a number of CADs that have previously 
been described elsewhere as either having an inhibitory 
effect on ASmase, or inducing generalized lipidosis. Our 
present report demonstrates a strong correlation between 
the degree of inhibition of ASmase and modulation of 
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MDR, whereas no correlation was observed between the 
capacity of these CADs to inhibit azidoprazosine photola- 
belling of P-gp and their ability to reverse the MDR 
phenotype. Moreover, the apparent link between inhibition 
of ASmase and modulation of MDR has permitted us to 
serendipitously discover three new modestly active 
chemosensitizers, trimipr~tmine, desipramine and mianser- 
inc. 
From the observations presented in this study it appears 
that CADs affect both the' activity of a lysosomal enzyme 
and the activity of a plasma membrane protein. We suggest 
that modulation of MDR by CADs may be the additive 
consequence of a direct inhibition of P-gp activity (i.e., 
drug binding) and an indirect mechanism based on the 
disruption of the lipid environment as indicated by the 
inhibition of ASmase and the ensuing phospholipidosis. 
We propose that the modification of lipid trafficking could 
interfere with the activity of P-gp, perhaps by affecting the 
ATP binding region or the drug-binding region. Spector 
and Burns [48] have previously suggested that changes in 
membrane lipid composition may perturb the function of 
integral proteins that span the lipid bilayer. It is also 
possible that the modified lipid constitution decreases the 
interaction between DOX and VBL with the plasma mem- 
brane. This would then lead to a decreased capture of drug 
within the lipid bilayer and a greater quantity gaining 
access to the intracellular targets. Similar hypotheses were 
recently proposed by Thierry et al. when they observed 
that empty liposomes inhibited [3H]vincristine binding to 
P-gp [44]. 
Of course, it is impossible at this point to rule out other 
mechanisms implicated in chemosensitization. I deed, 
CADs could also modulate MDR, perhaps by direct inter- 
action with the plasma membrane [13] or by mimicking 
sphingoid bases and inte.rfering with signal transduction 
pathways and/or protein kinase C [26,49], and also per- 
haps by disrupting intracellular drug trafficking [40]. How- 
ever, the assay for ASmase activity would still remain a 
useful tool for quantitative evaluation of the potency of a 
drug to induce lipidosis and indirectly modulate the MDR 
phenotype. It is important to note that the effects of these 
CADs on lipid composition did not increase the cytotoxic- 
ity of non-MDR drugs such as methotrexate, nor did they 
affect the cytotoxicity of DOX and VBL in the parental 
drug-sensitive c ll lines, 'which do not express P-gp, even 
though ASmase was quite similarly inhibited (data not 
shown). 
The lack of correlation between inhibition of azidopine 
P-gp photoaffinity labelling and modulation of MDR by 
certain compounds has previously been described 
[12,50,51]. It is of course possible for P-gp to have more 
than one drug binding :site, and also, as suggested by 
Zordan-Nudo et al., differences in displacing P-gp probes 
may be related to the ability of certain chemosensitizers to 
serve as substrates for P-gp efflux [14]. Indeed, P-gp 
substrates such as verapamil are less potent in inhibiting 
P-gp photoaffinity labelling by azidopine, as compared to 
Triton X-100 which is not effluxed from MDR cells [14]. 
Although it appears that all ASmase inhibitors will 
modulate MDR within a predictive range, all modulators 
of MDR do not inhibit ASmase. For example, verapamil 
and cyclosporin A, both potent MDR modulators, have no 
effect on ASmase activity (data not shown). However, 
both of these drugs have been described as having the 
ability of interfering with membrane biochemistry. Vera- 
pamil, for example, was shown by Ramu et al. to alter the 
lipid metabolism in P388/ADR cells by increasing the 
synthesis of phosphatidylcholine [52] and by Retzinger and 
Cohen to be specifically sequestered in and disrupting 
plasma membranes [53]. Finally, Niebylski and Petty have 
shown that cyclosporin A partitions into cellular mem- 
branes which may then undergo structural modifications 
[54]. 
In conclusion, the concept hat modifying the cellular 
lipid constitution by pharmacological gents can lead to 
the reversal of MDR may provide a new avenue of explo- 
ration for future research in screening and/or designing of 
potent chemosensitizers [55]. 
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